Vivos Therapeutics (NASDAQ:VVOS) Posts Quarterly Earnings Results

by · The Markets Daily

Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) posted its quarterly earnings results on Friday. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.11, Zacks reports. The business had revenue of $5.15 million for the quarter, compared to the consensus estimate of $5.63 million. Vivos Therapeutics had a negative return on equity of 2,325.64% and a negative net margin of 127.70%.

Here are the key takeaways from Vivos Therapeutics’ conference call:

  • Second-quarter revenue rose 35% to $5.2 million, driven by $1.9 million of additional service revenue from sleep testing and Vivos treatment. Gross profit increased to $3.0 million and gross margin improved to 57%.
  • Management reported several potential growth initiatives, including remote patient monitoring for an estimated 5,000–7,500 eligible CPAP patients, a planned CPAP DME program that could generate $150,000–$250,000 in monthly contribution margin, expanded EEG/insomnia services, and increased treatment-center capacity.
  • Vivos said referrals from Sleep Center of Nevada physicians to its treatment centers have increased three- to fourfold since the end of the quarter, with management expecting the resulting production to begin affecting third-quarter results. The company projects cash-flow positivity near the end of 2026 or early 2027 and significant positive EBITDA in fiscal 2027, subject to execution and reimbursement assumptions.
  • Liquidity remains a major risk: Vivos had only approximately $1.8 million in cash at June 30, used $9.2 million in operating cash during the first half, and stated that its cash is insufficient to fund the next 12 months. The company is not compliant with Nasdaq’s $2.5 million minimum stockholders’ equity requirement and may face delisting proceedings without additional equity financing and cost reductions.
  • Appliance revenue declined despite higher unit sales because of a shift toward lower-priced preformed products and away from higher-revenue CARE appliances. Meanwhile, proposed cardiology partnerships in Florida and Arizona are expected to require $800,000–$1 million of capital each, with revenue potentially beginning in the first or second quarter of 2027.

Vivos Therapeutics Stock Performance

VVOS traded up $0.04 during trading on Friday, hitting $0.34. The stock had a trading volume of 1,691,079 shares, compared to its average volume of 1,124,436. The stock has a 50 day simple moving average of $0.46 and a two-hundred day simple moving average of $0.92. Vivos Therapeutics has a twelve month low of $0.27 and a twelve month high of $5.12. The company has a market capitalization of $4.77 million, a PE ratio of -0.16 and a beta of 6.22.

Institutional Trading of Vivos Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. DRW Securities LLC lifted its position in Vivos Therapeutics by 179.5% during the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock worth $235,000 after acquiring an additional 74,441 shares during the period. Connective Capital Management LLC acquired a new stake in Vivos Therapeutics during the third quarter valued at $620,000. B. Riley Wealth Advisors Inc. acquired a new position in Vivos Therapeutics in the 2nd quarter worth about $220,000. Finally, XTX Topco Ltd acquired a new stake in Vivos Therapeutics in the second quarter valued at approximately $65,000. 26.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

VVOS has been the topic of a number of research reports. Ascendiant Capital Markets raised their target price on shares of Vivos Therapeutics from $3.00 to $3.10 and gave the company a “buy” rating in a research report on Thursday, June 4th. HC Wainwright dropped their price objective on shares of Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating on the stock in a research note on Friday, April 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $2.80.

View Our Latest Research Report on Vivos Therapeutics

Vivos Therapeutics Company Profile

(Get Free Report)

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.

Featured Stories